Concepta plc (LON: CPT) announced positive results from the hospital evaluations executed in China on its fertility product myLotus.
Concepta’s product is an alternative to blood testing in the China’s overloaded hospitals. MyLotus allows women to check for pregnancy and ovulation signs at home instead of seeking consultation at the hospital.
The results showed that myLotus is much more accurate than the existing commercial home tests. The evaluation for ovulation testing showed a 100 percent correlation between myLotus and regular blood tests. While, the evaluations for pregnancy testing achieved an impressive 98 percent correlation.
“I have been impressed with the performance of myLotus. This small, hand-held device is providing results that are comparable to large laboratory equipment. It opens up the opportunity for more flexibility in large and smaller hospitals but also for the women at home,” said Dr Yin Hui Rong, principal investigator at the Changhai Hospital Reproductive Centre.
China is the first market for an international launch of myLotus and the UK healthcare company signed last year an additional 3-year exclusive distribution agreement for myLotus with Huanzhong Biotech Ltd and Wanma Technology Co.
With a total market of 2.3 million women a year across the Hebei, Beijing, Lianoing and Shanghai areas, hospitals in China tend to be overcrowded.
“These results give doctors the confidence to recommend that couples should use myLotus to help them increase their chances of conceiving,” said Erik Henau, CEO of Concepta.
Concepta is a pioneer in UK healthcare. Their products target personalised mobile health concentrating mainly on women’s fertility and unexplained infertility.
Concepta shares were up 13 percent, trading at 0.88p, as of today at 12:00 pm (GMT).
